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Essentials
 Diagnosis of sitosterolemia, a rare recessive or syn-
dromic disorder, is usually delayed.
 Peripheral blood smear is extremely useful for establish-
ing the suspicion of sitosterolemia.
 High-throughput sequencing technology enables the
molecular diagnosis of inherited thrombocytopenias.
 Accurate characterization of sitosterolemia helps us
determine appropriate management.
Summary. Background: Sitosterolemia (STSL) is a reces-
sive inherited disorder caused by pathogenic variants in
the ABCG5 and ABCG8 genes. Increased levels of plasma
plant sterols (PSs) usually result in xanthomas and pre-
mature coronary atherosclerosis, although hematologic
abnormalities may occasionally be present. This clinical
picture is unfamiliar to many physicians, and patients
may be at high risk of misdiagnosis. Objectives: To report
two novel ABCG5 variants causing STSL in a Spanish
patient, and review the clinical and mutational landscape
of STSL. Patient/Methods: A 46-year-old female was
referred to us with lifelong macrothrombocytopenia. She
showed familial hypercholesterolemia-related xanthomas.
Molecular analysis was performed with high-throughput
sequencing. Plasma PS levels were evaluated with gas–liq-
uid chromatography. The STSL landscape was reviewed
with respect to specific online databases and all reports
published since 1974. Results: A blood smear revealed
giant platelets and stomatocytes. Novel compound
heterozygous variants were detected in exons 7
(c.914C>G) and 13 (c.1890delT) of ABCG5. The patient
showed an increased plasma level of sitosterol. These
findings support the diagnosis of STSL. In our review, we
identified only 25 unrelated STLS patients who presented
with hematologic abnormalities including macrothrombo-
cytopenia. It remains unknown why only some patients
develop hematologic abnormalities. Conclusions: This is
the first Spanish STSL patient to be reported and molecu-
larly characterized. The early diagnosis of STLS is
strongly supported by the presence of stomatocytes in
blood smears. The definitive diagnosis of STSL by mea-
surement of serum PS levels and molecular analyses
prompted the use of ezetimibe therapy.
Keywords: blood platelet disorders; genetic testing;
high-throughput nucleotide sequencing; sitosterols;
thrombocytopenia.
Introduction
Sitosterolemia (STSL), also known as phytosterolemia, is
a rare autosomal recessive inherited sterol storage disor-
der characterized by increased levels of plasma plant
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sterols (PSs), including stigmasterol, campesterol, and,
most abundantly, sitosterol [1]. STSL is caused by patho-
genic variants in the genes of two adjacent ATP-binding
cassette subfamily G members, i.e. members 5 and 8
(ABCG5 and ABCG8), which encode sterolin-1 and stero-
lin-2, respectively [2]. These proteins, which contain six
transmembrane domains and an ATP-binding domain,
travel as heterodimers to the apical membrane of the
enterocyte and the canalicular membrane of the biliary
tract, where they become full, active transporters of ster-
ols, although they require ATP to function [2,3]. Sterolins
regulate the network of absorption and excretion of sitos-
terol and cholesterol. In enterocytes, they promote the
flow of sitosterol back into the intestinal lumen and liver,
and the excretion of sterols into bile [3]. Like those of
other inherited thrombocytopenias (ITs), the prevalence
of STSL is unknown, although one Asian individual with
STSL was identified incidentally out of 2542 persons [4].
Clinical features of STLS usually include tendinous and
cutaneous xanthomas, premature coronary atherosclerosis
and derived complications, and arthritis or arthralgia [5].
These characteristics are shared with familial hypercholes-
terolemia (FH), so STSL may be misdiagnosed as
homozygous FH, especially in pediatric patients [6,7].
Unlike patients with FH, patients with STSL usually
respond well to a low-cholesterol diet and/or bile acid
sequestrants such as colestimide and colestyramine [6].
Hematologic abnormalities, e.g. hemolytic anemia (HA),
iron deficiency anemia, macrothrombocytopenia (i.e. large
platelets), abnormal bleeding, and/or splenomegaly, may
coexist with other clinical features [8]. These hematologic
problems have been occasionally reported as the only
clinical symptoms in otherwise asymptomatic STSL
patients [5,8]. Combined macrothrombocytopenia and
stomatocytosis, known as Mediterranean stomatocytosis/
macrothrombocytopenia, was initially described in
Mediterranean migrants to Australia [9]. The diagnosis of
STSL is usually delayed because many physicians are
unfamiliar with its clinical picture [5]. This delay is impor-
tant because, like patients with other ITs, non-diagnosed
patients may be at high risk of receiving inappropriate
treatment for a considerable period [8,10].
We report two novel ABCG5 variants causing syn-
dromic macrothrombocytopenia in a Spanish family, in a
case previously reported to be one of FH. We summarize
the clinical and mutational landscape of STSL in relation
to hematologic abnormalities, and propose some clinical
indications for a PS assay and for molecular analysis.
Patients and methods
The propositus was a 46-year-old female referred to us
with lifelong macrothrombocytopenia. Her medical his-
tory included palpebral surgery for xanthelasma on sev-
eral occasions, and clinical suspicion of FH. Her paternal
grandparents were first cousins. The patient suffered from
arthralgia and mild ecchymosis after trauma. Examina-
tions revealed no hepatosplenomegaly or clinically signifi-
cant lymphadenopathy, but she presented with
xanthelasmas (Fig. 1A). Bleeding was of minor relevance,
with an ISTH Bleeding Assessment Tool score of 1. Anal-
ysis of blood parameters showed the following: hemoglo-
bin level, 13.3 g dL1; reticulocytes, 2%; platelet count,
69.8 9 103 mm3. The mean platelet volume was 15.5 fL
(Sysmex XE 2100; Roche, Basel, Switzerland). No bio-
chemical abnormalities were found. Peripheral blood (PB)
smears revealed abnormally shaped erythrocytes (22%
stomatocytes) and giant platelets, some as large as the
erythrocytes (Fig. 1B). Platelet aggregation in response to
ADP and ristocetin was normal. The levels of platelet gly-
coprotein (GP) Ib–IX and GPIIb–IIIa measured by flow
cytometry were also normal (results not shown).
Given the syndromic macrothrombocytopenia, the
patient’s DNA was screened for molecular variants in 71
candidate genes related to inherited platelet disorders
(IPDs) by use of an established high-throughput sequenc-
ing (HTS) platform (MiSeq; Illumina, San Diego, CA,
USA) and accompanying variant analysis [10,11]. Serum
PS and cholesterol levels were quantified with gas–liquid
chromatography (GLC) [3]. Briefly, PSs and cholesterol
were isolated following alkaline hydrolysis and extraction
with organic solvent, and then analyzed with GLC in an
Agilent 7890 chromatograph fitted with a flame detector
(trimethylsilyl derivative; BSTFA 1%/TMCS in pyridine;
A
B
Fig. 1. Xanthelasma and peripheral blood film findings in the sitos-
terolemia patient. (A) Xanthelasma in the eyes. (B) Peripheral blood
smear revealed stomatocytes (black arrows) and macrothrombocytes
(gray arrow), consistent with hereditary sitosterolemia. [Color figure
can be viewed at wileyonlinelibrary.com]
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Sigma, St. Louis, MO, USA) in a DB1701 (S&W Scienti-
fic, Folsom, CA, USA) column. Epi-coprostanol (Sigma)
was used as the internal standard. Reference values
were from individuals aged 1–60 years whose cholesterol
metabolism was unaltered. The normal ranges (NRs) for
sitosterol, campesterol, b-cholestanol and cholesterol
were: < 10 lM, < 3 lM, 2.2–12.6 lM, and 1.7–6.6 mM,
respectively.
The study was performed in accordance with the Decla-
ration of Helsinki. The patient and healthy controls pro-
vided written informed consent.
Results and discussion
We report the clinical and molecular features, and treat-
ment outcome, of a patient presenting with xanthelasmas
who had been previously misdiagnosed with FH. Nota-
bly, her blood film showed prominent stomatocytes and
giant platelets (Fig. 1). It should be emphasized that care-
ful examination of the PB smear has been proposed as
the most important aspect of the diagnostic approach to
this disorder [12,13]. Some authors have also suggested
that platelet size should be reviewed in all patients with
hypercholesterolemia [5]. HA and thrombocytopenia are
hematologic abnormalities that are commonly encoun-
tered in daily practice; the coexistence of unexplained HA
with stomatocytosis and macrothrombocytopenia should
alert physicians to the possibility of STSL [14]. Neverthe-
less, these STSL-associated hematologic abnormalities are
still not recognized by most physicians, and many STSL
patients are not diagnosed until adulthood [12,15]. In
addition, STSL patients may suffer from long-term misdi-
agnosis of immune thrombocytopenia (ITP), Evans syn-
drome, or ITP secondary to arthritis. Consequently,
many STSL patients are treated with useless or even
harmful therapies, such as steroid therapy and/or splenec-
tomy, as occurs with other misdiagnosed ITs [10,12,15].
For the molecular analysis of this patient, we used a
novel HTS panel to simultaneously process a large num-
ber of genes involved in IPDs [10,11]. The HTS test
revealed novel compound heterozygote variations affect-
ing exons 7 (c.914C>G; p.T305R) and 13 (c.1890delT;
p.F630L fs8X) of ABCG5. As routine cholesterol mea-
surement methods do not discriminate cholesterol from
PSs, we used a specific GLC method [3,12] to determine
cholesterol and PS levels separately. The patient’s choles-
terol level was 2.7 mM, which was in the NR, owing to
her previous treatment with statins. Measurements of
plasma PS levels revealed high concentrations of sitosterol
(668.2 lM), campesterol (169.6 lM), and b-cholestanol
(30.7 lM). These findings confirmed the diagnosis of
STSL in our patient. There was a striking delay of dec-
ades between the onset of symptoms and the STLS diag-
nosis. Long delays in providing a definitive diagnosis
have also been reported in other cases of STLS [12]. Such
delays are not inconsequential, as they can lead to
inappropriate clinical management, including delayed PS
restriction and administration of sterol absorption inhibi-
tor [6], and a subsequent risk of advanced atherosclerotic
cardiovascular disease and poorer clinical outcome in
affected patients. Following her definitive STLS diagnosis,
our patient began ezetimibe therapy, which effectively
decreased the plasma levels of total cholesterol and LDL
cholesterol [16]. Although ezetimibe has been shown to
improve thrombocytopenia in ABCG5-knockout mice,
this benefit has not been consistently found in humans
[17,18]. After 4 months of ezetimibe treatment, sitosterol
levels were reduced by 30% (473.1 lM), whereas choles-
terol (2.4 mM), campesterol (156.3 lM) and b-cholestanol
(23 lM) levels remained similar. However, our patient still
showed moderate macrothrombocytopenia (platelet
count: 80.9 9 103 mm3).
Since the first description of this disorder in 1974, < 100
related cases have been found worldwide [1,4,12]. To our
knowledge, only 25 unrelated STSL patients presenting
with hematologic abnormalities at the time of diagnosis
have been reported, some of whom had been previously
misdiagnosed with ITP or HA, and had therefore under-
gone splenectomy (Table 1). Most of these described fami-
lies were consanguineous. Although consanguinity was
detected in this pedigree, the patient had a compound
heterozygosis, so the family relationship is unlikely to be
relevant here (Fig. 2A). The mechanism by which sitos-
terol accumulation might negatively affect platelet struc-
ture and function is not well understood. Whereas some
authors have described decreased platelet activation
responsiveness in animal models of sitosterolemia [19],
others have identified platelet hyperactivation, reduced
aIIbb3 surface expression, loss of GPIba–FlnA linkage,
and microparticle formation [17]. As in previous STLS
cases (Table 1) [12], our patient showed almost negligible
bleeding diathesis and no platelet defects with respect to
aggregation or the expression of major GPs.
The molecular pathology involved in STSL affects
ABCG5 and ABCG8 [20,21]. These two genes probably
evolved from a common ancestral gene by a tandem
duplication and inversion event. The intergenic region
between ABCG5 and ABCG8 is very small (< 160 bases)
and contains no conserved TATA motif(s), suggesting
that transcriptional factors help to regulate this locus
[22]. Moreover, mutational founder effects underlie many
of the cases, suggesting that this disease has been present
for many generations, perhaps for > 4000 years [23].
However, despite the close proximity and homology of
ABCG5 and ABCG8, considerably more polymorphisms
are present in ABCG8 than in ABCG5 [23]. Caucasians
(mostly of northern European origin) frequently carry
mutations in ABCG8, whereas Chinese, Japanese and
Indian patients often have mutations in ABCG5 (Table 1)
[6]. Among these, 35% and 65% feature homozygous or
compound heterozygous variants in ABCG5 and ABCG8,
respectively [6,24]. Some heterozygotes showed higher
© 2017 International Society on Thrombosis and Haemostasis
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than normal PS levels, but these were still substantially
lower than those in homozygotes [25].
Twenty-eight variants have previously been reported in
the ABCG5 gene (Table 1; Fig. 3), and only six variants
are present in more than one patient. Several of these are
nonsense variants (eight) or frameshift variants (three), or
affect the splicing site (eight) or code for truncated
polypeptides (two). Others are missense variants (seven)
that interfere with the formation of stable ABCG5–
ABCG8 heterodimers and their trafficking out of the
endoplasmic reticulum [6,26–29] (Fig. 3).
Only 11 of the 28 reported variants are associated with
macrothrombocytopenia (Fig. 3). The patient reported
here carries two variants affecting exons 7 and 13 of
the ABCG5 gene. The former, c.914C>G; p.T305R, a
rare single-nucleotide polymorphism (SNP) (rs143740796)
with a minor allele frequency of 0.00002486 (http://exac.b
roadinstitute.org), is predicted to be pathogenic by
in silico models (SIFT, POLYPHEN-2, MUTATIONASSESSOR, and
MUTATIONTASTER). This SNP affects highly conserved resi-
dues at the N-terminal domain, in the intracytoplasmic
region of the ABCG5 protein [3]. The remarkable degree
of conservation of the STSL locus in fish, amphibians,
rodents and humans suggests that the polymorphic
changes may have a dramatic effect on function [3]. The
second genetic variant in the patient is a novel microdele-
tion in exon 13 (c.1890delT; p.F630L fs8X) that causes
replacement of phenylalanine by leucine at amino acid
position 630, producing a frameshift and stop codon at
amino acid 638 (Fig. 2B).
F1: WT F2: c.914C>G F4: not
analyzed
F3: c.1890delT
P1: c.914C>G and c.1890delT
P1 and F3: c.1890delT
P1 and F2: c.914C>G
A B
Fig. 2. Family pedigree and chromatogram showed the variants in ABCG5. (A) Family pedigree. The propositus (P1) was compound heterozy-
gous (c.914G>C and c.1980delT). Heterozygous family members are shown as half-filled symbols. The father (F4) was deceased, and therefore
could not be analyzed. (B) Chromatogram: the proband (P1) showed compound heterozygosity for c.914G>C and c.1980delT, whereas F2 and
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Fig. 3. Molecular landscape of variants reported in ABCG5 and ABCG8. The structures of ABCG5 and ABCG8, comprising 13 exons, are
shown. Reported variants are indicated above each gene structure. Red symbols indicate patients with macrothrombocytopenia, and italics indi-
cate recurrent variants (i.e. appearing in more than one patient). Asterisks (*) indicate genetic variants associated with hematologic abnormali-
ties in some patients. [Color figure can be viewed at wileyonlinelibrary.com]
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The heterogeneous landscape of STSL may be related
both to other genetic factors and to environmental condi-
tions, which can modify gene expression or sterol absorp-
tion [15]. For example, an olive oil-rich diet contributes
to elevated PS levels in blood [15]. Phenotypic hetero-
geneity could also arise by gene conversion that restores
the wild-type sequence of the maternal or the paternal
allele, converting the compound heterozygous condition
to a simple heterozygous one, in the form of mosaicism
[26].
The underlying mechanism responsible for the hema-
tologic abnormalities observed in some patients with
STSL is most likely the accumulation of circulating PSs
in blood cell membranes, leading to their abnormal
morphology and function [29]. Thus, excess PS levels
promote membrane stiffness and predispose to rupture.
Likewise, PS enrichment in platelet membranes might
affect their size, number, and function, which could be
related to bleeding episodes [29]. These hypotheses were
suggested to explain the behavior of ABCG5-deficient
and ABCG8-deficient mice [17,19]. In humans, however,
only some patients with STSL show hematologic abnor-
malities. Moreover, some variants, such as R419H and
R446X (ABCG5), are associated with thrombocytopenia,
although not in all patients, implying that unknown
mechanisms are also involved (Table 1). Our screening
of 71 genes related to IPD yielded no candidate vari-
ants other than those mentioned above. It has been
suggested that whole-exome or whole-genome analysis
might identify new genetic determinants that predispose
patients to having these clinical conditions.
In summary, we have characterized the first case of
STSL in a Spanish patient by using a novel HTS multi-
genic platform for an initial molecular survey. A defini-
tive diagnosis of STSL based on the measurement of
serum PS levels prompted the use of ezetimibe therapy,
which effectively reduced serum PS levels. It is essential
to suspect and correctly diagnose this controllable disor-
der to ensure its proper management, and prevent cardio-
vascular diseases.
Addendum
R. Benito, K. Janusz, and J.M. Hernandez-Sanchez
undertook the molecular studies. J. M. Bastida, S. Mar-
cellini, M. Dıez-Campelo, A. Hortal, M. Giros, J. Rivera,
and M. L. Lozano interpreted the clinical and laboratory
data, blood smears, PS plasma levels, platelet aggrega-
tion, and flow cytometry. J. M. Bastida and R. Benito
interpreted the molecular analyses. J. M. Bastida wrote
the manuscript. J. M. Hernandez-Rivas, M. L. Lozano, J.
Rivera, and J.R. Gonzalez-Porras critically reviewed the
manuscript. J. M. Hernandez-Rivas was the principal
investigator. All authors read and approved the final
manuscript.
Acknowledgements
We gratefully acknowledge the patient and her family
members. We are grateful to I. Rodrıguez and S.
Gonzalez for their help in isolating DNA, and to P.
Mason for his attention to some technical aspects. This
work was partially supported by grants from the Gerencia
Regional de Salud (GRS 1370/A/16), ISCIII & Feder
(PI14/01956), CIBERER CB15/00055, Fundacion Seneca
(19873/GERM/15), and Sociedad Espa~nola de Trombosis
y Hemostasia (SETH).
Disclosure of Conflict of Interests
The authors state that they have no conflict of interest.
References
1 Bhattacharyya AK, Connor WE. Beta-sitosterolemia and xan-
thomatosis. A newly described lipid storage disease in two sisters.
J Clin Invest 1974; 53: 1033–43.
2 Hubacek JA, Berge KE, Cohen JC, Hobbs HH. Mutations in
ATP-cassette binding proteins G5 (ABCG5) and G8 (ABCG8)
causing sitosterolemia. Hum Mutat 2001; 18: 359–60.
3 Kidambi S, Patel SB. Sitosterolaemia: pathophysiology, clinical
presentation and laboratory diagnosis. J Clin Pathol 2008; 61:
588–94.
4 Yoo EG. Sitosterolemia: a review and update of pathophysiol-
ogy, clinical spectrum, diagnosis, and management. Ann Pediatr
Endocrinol Metab 2016; 21: 7–14.
5 Rees DC, Iolascon A, Carella M, O’Marcaigh AS, Kendra JR,
Jowitt SN, Wales JK, Vora A, Makris M, Manning N, Nicolaou
A, Fisher J, Mann A, Machin SJ, Clayton PT, Gasparini P, Ste-
wart GW. Stomatocytic haemolysis and macrothrombocytopenia
(Mediterranean stomatocytosis/macrothrombocytopenia) is the
haematological presentation of phytosterolaemia. Br J Haematol
2005; 130: 297–309.
6 Ono S, Matsuda J, Saito A, Yamamoto T, Fujimoto W, Shimizu
H, Dateki S, Ouchi K. A case of sitosterolemia due to compound
heterozygous mutations in ABCG5: clinical features and treat-
ment outcomes obtained with colestimide and ezetimibe. Clin
Pediatr Endocrinol 2017; 26: 17–23.
7 Renner C, Connor WE, Steiner RD. Sitosterolemia presenting as
pseudohomozygous familial hypercholesterolemia. Clin Med Res
2016; 14: 103–8.
8 Wang G, Cao L, Wang Z, Jiang M, Sun X, Bai X, Ruan C.
Macrothrombocytopenia/stomatocytosis specially associated with
phytosterolemia. Clin Appl Thromb Hemost 2012; 18: 582–7.
9 Stewart GW, Lloyd J, Pegel K. Mediterranean stomatocytosis/
macrothrombocytopenia: update from Adelaide, Australia. Br J
Haematol 2006; 132: 651–61.
10 Bastida JM, Del Rey M, Revilla N, Benito R, Perez-Andres M,
Gonzalez B, Riesco S, Janusz K, Padilla J, Benito-Sendin AH,
Bueno D, Blanco E, Hernandez-Rivas M, Vicente V, Rivera J,
Gonzalez-Porras R, Lozano ML. Wiskott–Aldrich syndrome in a
child presenting with macrothrombocytopenia. Platelets 2017; 28:
417–20.
11 Lozano ML, Cook A, Bastida JM, Paul DS, Iruin G, Cid AR,
Adan-Pedroso R, Ramon Gonzalez-Porras J, Hernandez-Rivas
JM, Fletcher SJ, Johnson B, Morgan N, Ferrer-Marin F, Vicente
V, Sondek J, Watson SP, Bergmeier W, Rivera J. Novel muta-
tions in RASPGRP2 encoding for CalDAG-GEFI abrogate
© 2017 International Society on Thrombosis and Haemostasis
Diagnosis and genetics landscape of sitosterolemia 1865
Rap1 activation causing platelet dysfunction. Blood 2016; 128:
1282–9.
12 Wang Z, Cao L, Su Y, Wang G, Wang R, Yu Z, Bai X, Ruan
C. Specific macrothrombocytopenia/hemolytic anemia associated
with sitosterolemia. Am J Hematol 2014; 89: 320–4.
13 Goodyer M, Lovey J, Menetrey MJ. Peripheral blood features of
phytosterolaemia. Br J Haematol 2015; 171: 669.
14 Kaya Z, Niu DM, Yorulmaz A, Tekin A, G€ursel T. A novel
mutation of ABCG5 gene in a Turkish boy with phytosterolemia
presenting with macrothrombocytopenia and stomatocytosis.
Pediatr Blood Cancer 2014; 61: 1457–9.
15 Keller S, Prechtl D, Aslanidis C, Ceglarek U, Thiery J, Schmitz
G, Jahreis G. Increased plasma plant sterol concentrations and a
heterozygous amino acid exchange in ATP binding cassette
transporter ABCG5: a case report. Eur J Med Genet 2011; 54:
e458–60.
16 Othman RA, Myrie SB, Mymin D, Merkens LS, Roullet JB,
Steiner RD, Jones PJ. Ezetimibe reduces plant sterol accumula-
tion and favorably increases platelet count in sitosterolemia. J
Pediatr 2015; 166: 125–31.
17 Kanaji T, Kanaji S, Montgomery RR, Patel SB, Newman PJ.
Platelet hyperreactivity explains the bleeding abnormality and
macrothrombocytopenia in a murine model of sitosterolemia.
Blood 2013; 122: 2732–42.
18 Quintas-Cardama A, McCarthy JJ. Long-term follow-up of a
patient with sitosterolemia and hemolytic anemia with excellent
response to ezetimibe. Genet Disor Genet Rep 2013; 2: 1.
19 Chase TH, Lyons BL, Bronson RT, Foreman O, Donahue LR,
Burzenski LM, Gott B, Lane P, Harris B, Ceglarek U, Thiery J,
Wittenburg H, Thon JN, Italiano JE Jr, Johnson KR, Shultz
LD. The mouse mutation ‘thrombocytopenia and cardiomyopa-
thy’ (trac) disrupts Abcg5: a spontaneous single gene model for
human hereditary phytosterolemia/sitosterolemia. Blood 2010;
115: 1267–76.
20 Graf GA, Cohen JC, Hobbs HH. Missense mutations in ABCG5
and ABCG8 disrupt heterodimerization and trafficking. J Biol
Chem 2004; 279: 24881–8.
21 Togo M, Toda T, Nguyen LA, Kubota S, Tsukamoto K, Satoh
H, Hara M, Iso-o N, Noto H, Kimura S, Nakahara K, Seyama
Y, Hashimoto Y. Genetic analysis of phytosterolaemia. J Inherit
Metab Dis 2001; 24: 43–50.
22 Wang GF, Wang ZY, Cao LJ, Jiang MH, Sun XH, Bai X, Ruan
CG. Clinical and gene study of three pedigrees of phytos-
terolemia associated with macrothrombocytopenia and hemoly-
sis. Zhonghua Xue Ye Xue Za Zhi 2011; 32: 331–6.
23 Hazard SE, Patel SB. Sterolins ABCG5 and ABCG8: regula-
tors of whole body dietary sterols. Pflugers Arch 2007; 453:
745–52.
24 Wang G, Wang Z, Liang J, Cao L, Bai X, Ruan C. A phytos-
terolemia patient presenting exclusively with macrothrombocy-
topenia and stomatocytic hemolysis. Acta Haematol 2011; 126:
95–8.
25 Kratz M, Kannenberg F, Gramenz E, Berning B, Trautwein E,
Assmann G, Rust S. Similar serum plant sterol responses of
human subjects heterozygous for a mutation causing sitos-
terolemia and controls to diets enriched in plant sterols or sta-
nols. Eur J Clin Nutr 2007; 61: 896–905.
26 Colima Fausto AG, Gonzalez Garcıa JR, Wong Ley Madero
LE, Maga~na Torres MT. Two novel mutations in the ABCG5
gene, c.144-1G>A and c.1523 delC, in a Mexican family with
sitosterolemia. J Clin Lipidol 2016; 10: 204–8.
27 Heimerl S, Langmann T, Moehle C, Mauerer R, Dean M, Beil
FU, von Bergmann K, Schmitz G. Mutations in the human
ATP-binding cassette transporters ABCG5 and ABCG8 in sitos-
terolemia. Hum Mutat 2002; 20: 151.
28 Melenotte C, Carrie A, Serratrice J, Weiller PJ. Sitosterolemia: a
new mutation in a Mediterranean patient. J Clin Lipidol 2014; 8:
451–4.
29 Su Y, Wang Z, Yang H, Cao L, Liu F, Bai X, Ruan C. Clinical
and molecular genetic analysis of a family with sitosterolemia
and co-existing erythrocyte and platelet abnormalities. Haemato-
logica 2006; 91: 1392–5.
30 Neff AT. Sitosterolemia’s stomatocytosis and macrothrombocy-
topenia. Blood 2012; 120: 4283.
© 2017 International Society on Thrombosis and Haemostasis
1866 J. M. Bastida et al
